BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37339979)

  • 1. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
    Heumann T; Judkins C; Li K; Lim SJ; Hoare J; Parkinson R; Cao H; Zhang T; Gai J; Celiker B; Zhu Q; McPhaul T; Durham J; Purtell K; Klein R; Laheru D; De Jesus-Acosta A; Le DT; Narang A; Anders R; Burkhart R; Burns W; Soares K; Wolfgang C; Thompson E; Jaffee E; Wang H; He J; Zheng L
    Nat Commun; 2023 Jun; 14(1):3650. PubMed ID: 37339979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
    Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
    Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
    Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
    J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.
    Li K; Tandurella JA; Gai J; Zhu Q; Lim SJ; Thomas DL; Xia T; Mo G; Mitchell JT; Montagne J; Lyman M; Danilova LV; Zimmerman JW; Kinny-Köster B; Zhang T; Chen L; Blair AB; Heumann T; Parkinson R; Durham JN; Narang AK; Anders RA; Wolfgang CL; Laheru DA; He J; Osipov A; Thompson ED; Wang H; Fertig EJ; Jaffee EM; Zheng L
    Cancer Cell; 2022 Nov; 40(11):1374-1391.e7. PubMed ID: 36306792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
    Khushalani NI; Ott PA; Ferris RL; Cascone T; Schadendorf D; Le DT; Sharma MR; Barlesi F; Sharfman W; Luke JJ; Melero I; Lathers D; Neely J; Suryawanshi S; Sanyal A; Holloway JL; Suryawanshi R; Ely S; Segal NH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
    Saung MT; Zheng L
    Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
    Tsujikawa T; Crocenzi T; Durham JN; Sugar EA; Wu AA; Onners B; Nauroth JM; Anders RA; Fertig EJ; Laheru DA; Reiss K; Vonderheide RH; Ko AH; Tempero MA; Fisher GA; Considine M; Danilova L; Brockstedt DG; Coussens LM; Jaffee EM; Le DT
    Clin Cancer Res; 2020 Jul; 26(14):3578-3588. PubMed ID: 32273276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
    Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
    Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
    Le DT; Picozzi VJ; Ko AH; Wainberg ZA; Kindler H; Wang-Gillam A; Oberstein P; Morse MA; Zeh HJ; Weekes C; Reid T; Borazanci E; Crocenzi T; LoConte NK; Musher B; Laheru D; Murphy A; Whiting C; Nair N; Enstrom A; Ferber S; Brockstedt DG; Jaffee EM
    Clin Cancer Res; 2019 Sep; 25(18):5493-5502. PubMed ID: 31126960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
    Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
    Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
    Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
    Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
    J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
    Wu AA; Bever KM; Ho WJ; Fertig EJ; Niu N; Zheng L; Parkinson RM; Durham JN; Onners B; Ferguson AK; Wilt C; Ko AH; Wang-Gillam A; Laheru DA; Anders RA; Thompson ED; Sugar EA; Jaffee EM; Le DT
    Clin Cancer Res; 2020 Oct; 26(19):5129-5139. PubMed ID: 32591464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
    Foster CC; Fleming GF; Karrison TG; Liao CY; Desai AV; Moroney JW; Ratain MJ; Nanda R; Polite BN; Hahn OM; O'Donnell PH; Vokes EE; Kindler HL; Hseu R; Janisch LA; Dai J; Hoffman MD; Weichselbaum RR; Pitroda SP; Chmura SJ; Luke JJ
    Clin Cancer Res; 2021 Oct; 27(20):5510-5518. PubMed ID: 34168049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
    Bassani-Sternberg M; Digklia A; Huber F; Wagner D; Sempoux C; Stevenson BJ; Thierry AC; Michaux J; Pak H; Racle J; Boudousquie C; Balint K; Coukos G; Gfeller D; Martin Lluesma S; Harari A; Demartines N; Kandalaft LE
    Front Immunol; 2019; 10():1832. PubMed ID: 31440238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
    Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
    Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.